Clinical Trial Update: A Phase III Study to Evaluate the Efficacy and Safety of GSK1358820 in Subjects With Post-stroke Upper Limb Spasticity [Phase 3]

View source ↗

Summary

Phase III trial evaluating GSK1358820 for post-stroke upper limb spasticity has completed with results posted in 2019.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Post-stroke Spasticity
• Spasticity

Drugs mentioned

• GSK1358820

Snippet

Sponsor: GlaxoSmithKline | Conditions: Spasticity, Post-Stroke | Phase 3 | Status: COMPLETED | Results posted: 2019-10-18